OS Fund is an American venture capital firm established in October 2014 by Bryan Johnson, who allocated $100 million from the sale of Braintree to PayPal, and Jeff Klunzinger. The firm focuses on early-stage investments in science and technology sectors, particularly in genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics. (

The name "OS Fund" is derived from the acronym for "operating system," symbolizing the firm's commitment to foundational technologies that drive innovation.

In September 2015, OS Fund publicly released its investment methodology in synthetic biology to encourage broader investment in emerging sciences.

Notable investments include Ginkgo Bioworks, a Boston-based biotechnology company valued at $8.7 billion, Atomwise, an AI-powered drug discovery platform, and Matternet, a company developing drone logistics networks for on-demand goods transport. (

OS Fund seeks to partner with visionary entrepreneurs who aim to commercialize breakthrough discoveries and author a better future for humanity.